Infliximab biosimilar - Pfizer

Drug Profile

Infliximab biosimilar - Pfizer

Alternative Names: GP1111; Infliximab-Pfizer; Infliximab-qbtx; IXIFI; PF 06438179; PF 6438179

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 13 Dec 2017 Registered for Ulcerative colitis (Treatment-experienced), Crohn's disease (In adolescents, In adults, In children, Treatment-experienced), Rheumatoid arthritis (Combination therapy, Treatment-experienced), Plaque psoriasis, Psoriatic arthritis and Ankylosing spondylitis in USA (IV) - First Global Approval
  • 03 Nov 2017 Efficacy, adverse events and immunogenicity data from the phase III REFLECTIONS B537-02 trial presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 01 Jun 2017 Pfizer completes a phase-III trials in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in USA, Poland, Lithuania, Hungary, Australia, Bosnia-Herzegovina, Brazil, Bulgaria, Canada, Czech Republic, Georgia, Guatemala, Germany, Israel, Japan, Jordan, South Korea, Mexico, Morocco, Peru, Philippines, Romania, Russia, Serbia, South Africa, Tunisia, Ukraine, France, United Kingdom (IV) (NCT02222493) (EudraCT2013-004148-49)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top